cevimeline hydrochloride
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer, Oral Complications, Radiation Toxicity
Trial Timeline
Jun 1, 2001 → Mar 1, 2003
NCT ID
NCT00017511About cevimeline hydrochloride
cevimeline hydrochloride is a phase 3 stage product being developed by Daiichi Sankyo for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00017511. Target conditions include Head and Neck Cancer, Oral Complications, Radiation Toxicity.
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Cancer were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00017511 | Phase 3 | Completed |
Competing Products
20 competing products in Head and Neck Cancer